This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
For example, tellurium-123 was reported to be radioactive, but the same experimental group later retracted this report, and it is again listed as stable. The next group is the primordial radioactive nuclides. These have been measured to be radioactive, or decay products have been identified in natural samples (tellurium-128, barium-130). There are 35 of these (see these nuclides), of which 25 have half-lives longer than 1013 years. For most of these 25, decay is difficult to observe, and for most purposes they can be regarded as effectively stable. Bismuth-209 is notable as it is the only naturally occurring isotope of an element long considered stable. The other 10, platinum-190, samarium-147, lanthanum-138, rubidium-87, rhenium-187, lutetium-176, thorium-232, uranium-238, potassium-40, and uranium-235, have half-lives between 7×108 and 5×1011 years, which means they have undergone at least 0.5% depletion since the formation of the Solar System about 4.6×109 years ago, but still exist on Earth in significant quantities. They are the primary source of radiogenic heating and radioactive decay products. Together, there are a total of 286 primordial nuclides. The list then covers the other radionuclides with half-lives longer than 1 hour, split into several tables in order of successively shorter lifetimes. Some nuclides that have half-lives too short to be primordial can be detected in nature as a result of later production by natural processes, mostly in trace amounts.
=== Development === Thyrotrophs can be identified via immunocytochemistry as early as the 12th week of fetal development, roughly at the same time that gonadotrophs can be detected. The active hormone, TSH, is detected at the 14th week of gestation. Transcription factors, such as Pit-1, GATA-2, and PROP1, influence cell proliferation and maturation.
On New Year's Day 1942, the representatives of Allied "Big Four", the United States, the United Kingdom, the Soviet Union, and China, signed a short document which later came to be known as the Declaration by United Nations and the next day the representatives of twenty-two other nations added their signatures. President Roosevelt initiated post-war plans for the creation of a new and more durable international organization that would replace the former League of Nations. Roosevelt's Four Policemen proposal received criticism from liberal internationalists who wanted power to be more evenly distributed among nations. Internationalists were concerned that the Four Policemen could lead to a new Quadruple Alliance. A new plan for the United Nations was drafted by the State Department in April 1944. It kept the emphasis on great power solidarity that was central to Roosevelt's Four Policemen proposal for the United Nations. The members of the Big Four would serve as permanent members of the United Nations Security Council. Each of the four permanent members would be given a United Nations Security Council veto power, which would override any UN resolution that went against the interests of one of the Big Four. However, the State Department had compromised with the liberal internationalists. Membership eligibility was widened to include all nation states fighting against the Axis powers instead of a select few. Roosevelt had been a supporter of the League of Nations back in 1919–1920, but was determined to avoid the mistakes Woodrow Wilson had made.
=== Organic synthesis === Copper sulfate is employed at a limited level in organic synthesis. The anhydrous salt is used as a dehydrating agent for forming and manipulating acetal groups. The hydrated salt can be intimately mingled with potassium permanganate to give an oxidant for the conversion of primary alcohols.
These errors or mutations lead to the expression of a mutant huntingtin protein, which contains repetitive glutamine residues that are encoded by expanding CAG trinucleotide repeats in the gene. Huntington's disease is characterized by neuronal loss and gliosis. Symptoms of the disease include: movement disorder, cognitive decline, and behavioral disorder.
Sources: en.wikipedia.org
The flora of the Appalachians are diverse and vary primarily in response to geology, latitude, elevation and moisture availability. Geobotanically, they constitute a floristic province of the North American Atlantic Region. The Appalachians consist primarily of deciduous broad-leaf trees and evergreen needle-leaf conifers, but also contain the evergreen broad-leaf American holly (Ilex opaca), and the deciduous needle-leaf conifer, the tamarack, or eastern larch (Larix laricina). The dominant northern and high elevation conifer is the red spruce (Picea rubens), which grows from near sea level to above 4,000 ft (1,200 m) above sea level (asl) in northern New England and southeastern Canada. It also grows southward along the Appalachian crest to the highest elevations of the southern Appalachians, as in North Carolina and Tennessee. In the central Appalachians it is usually confined above 3,000 ft (900 m) asl, except for a few cold valleys in which it reaches lower elevations. In the southern Appalachians, it is restricted to higher elevations. Another species is the black spruce (Picea mariana), which extends farthest north of any conifer in North America, is found at high elevations in the northern Appalachians, and in bogs as far south as Pennsylvania. The Appalachians are also home to two species of fir, the boreal balsam fir (Abies balsamea), and the southern high elevation endemic, Fraser fir (Abies fraseri).
Glycerol is a stable preserving agent for botanical extracts that, when utilized in proper concentrations in an extraction solvent base, does not allow inverting or reduction-oxidation of a finished extract's constituents, even over several years. Both glycerol and ethanol are viable preserving agents. Glycerol is bacteriostatic in its action, and ethanol is bactericidal in its action.
The doctor who had ordered the tests was a diabetes expert who specialised in insulin and hypoglycaemic episodes, and she had believed the incident to be suspicious. No doctor or medical staff member had prescribed her this drug, and she had no condition that required it to be issued. The amount of insulin in Hall's blood was about 12 times the normal level, and it had been injected into her system. The insulin was manufactured and not produced naturally in the body. It had been injected into her abdomen, as indicated by the fact that a bulge was found under her skin there that was consistent with a large injection of fluid. Doctors believed it was done by someone with nursing or medical experience. The results of the tests led the hospital to contact the police. It was discovered after Hall's death that insulin had also been taken from the storage fridge, and Norris later admitted that he was the last person to have accessed this fridge before Hall had been injected with insulin. Two vials of insulin were found to have been taken from the fridge, which had to have been taken by someone during the night shift which Norris was working when Hall became unwell. Norris had on a previous occasion been caught stealing drugs from the hospital. Norris also admitted that he was the last person to see Hall at 4.30 am, half an hour before she fell into the hypoglycaemic coma. at around 5 am.
=== ADHD === Attention deficit hyperactivity disorder is a neurodevelopmental condition involving problems with attention, hyperactivity, and impulsiveness. It is most commonly treated using stimulant drugs such as methylphenidate (Ritalin), whose primary effect is to increase dopamine levels in the brain, but drugs in this group also generally increase brain levels of norepinephrine, and it has been difficult to determine whether these actions are involved in their clinical value. There is also substantial evidence that many people with ADHD show biomarkers involving altered norepinephrine processing. Several drugs whose primary effects are on norepinephrine, including guanfacine, clonidine, and atomoxetine, have been tried as treatments for ADHD, and found to have effects comparable to those of stimulants.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.